welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer jumps on 7-year-old data
Acer Therapeutics Inc. had a welcoming first week on the Nasdaq stock exchange, seeing shares sruge more 10% Monday after verifying positive clinical results published almost seven years ago from a study of celiprolol, the active ingredient in its lead drug candidate.
The study tested celiprolol against placebo in patients with vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening disorder that causes arteries and organs to easily rupture. After receiving treatment for about four years on average, 20% of the participants in the investigational arm experienced arterial events versus 50% of those in the control arm.
expertly curated content related to this topic
-
Ehlers-Danlos SyndromeM. E., female, aged 16. Present conditi...
-
Ehlers-Danlos SyndromePatient aged 46, single, housemaid. She ...
-
Ehlers-Danlos Society Receives Transformational Gift to Accelerate Genomic Research into Hypermobile EDSThe Ehlers-Danlos Society has announced ...